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Dendritic cells play a major role in the generation of immunity against tumour cells. They can be grown under various culture
conditions, which inﬂuence the phenotypical and functional properties of dendritic cells and thereby the consecutive immune
response mainly executed by T cells. Here we discuss various conditions, which are important during generation and
administration of dendritic cells to elicit a tumouricidal T cell-based immune response.
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Cytotoxic T-cells (CTL) are the most efﬁcient cells concerning
defence against tumour cells (Lanzavecchia, 1993). One of the
major questions in tumour immunology is, how an efﬁcient
CTL-response can be generated to elicit an antigen-speciﬁc and
protective T-cell response in vivo. It has been shown that the
immune response to tumour antigens and other antigens is altered
in patients with cancer. These alterations concern many elements of
the immune response and prevent effective proliferation of
tumour-antigen speciﬁc T cells and their subsequent recognition
of tumour cells. In recent studies antigen-presenting cells (APC)
have been shown to play a crucial role in the induction of
tumour-protective immune responses by generating tumour-speci-
ﬁc T cells (Lanzavecchia, 1993). Antigen receptors (TCR) of
tumour-speciﬁc T cells recognise tumour-associated peptides that
are presented in the context of HLA class-I or class-II molecules
by the APC. Successful recognition of tumour–antigen by the T-
cell is not only dependent on TCR-peptide-HLA-interaction, but
other co-stimulatory signals must be provided to prevent anergy
(Schwartz, 1990). These are mainly CD80/CD86–CD28- or
CD40–CD40L-interactions (Bennett et al, 1998). These interac-
tions do not only underline the importance of T cells, but also
the signiﬁcant role of dendritic cells (DC), which are the most
potent antigen-presenting cells among others like monocytes,
macrophages and B cells.
Several in vitro and in vivo studies showed the ability of vaccina-
tion with DC to elicit tumour-speciﬁc T-cell immunity (Schuler
and Steinman, 1997). This result implies that (1) DC might be just
another altered element of the immune system or (2) DC are able
to overcome tumour-protective alterations in cancer patients by
inducing effective CTL response or (3) both. In this context a
phenotypic and functional dichotomy of DC in DC1 and DC2
appears to be of importance. DC1 and DC2 cells were found to
produce different cytokines and thereby induce TH1 and TH2
differentiation, respectively. The lymphoid-related DC (DC2) are
CD11c
7 and have been shown to induce a tolerating response vs
tumour cells by activating mainly TH2 cells, whereas myeloid-
derived DC (DC1) are immunostimulatory via TH1 cells. Develop-
ment of TH2-promoting DC2 cells is inhibited by cytokines (IL-4)
produced by TH2 cells. In contrast, development of TH1-promoting
DC1 cells is enhanced by the TH2 cytokine IL-4 (Banchereau and
Steinman, 1998; Rissoan et al, 1999).
Vaccination with peptide- or lysate-pulsed DC showed the clin-
ical efﬁciency in the induction of a curative tumour-speciﬁc
therapy in metastatic melanoma and other malignancies (Table 1;
Thurner et al, 1999a). In a study performed with peptide- and
lysate-pulsed DC ﬁve out of 16 patients showed at least a partial
remission, two of them a complete remission (Nestle et al, 1998).
Monocytes drawn from peripheral blood were grown in the
presence of a cytokine cocktail (GM–CSF, IL-4, IL-1b, IL-6,
TNF-a, PgE2) to DC, which display mainly the DC1-phenotype.
Subsequently, DC were pulsed with peptides or autologous
tumour-lysate and injected back into the patient with different
clinical outcome.
Several factors seem to inﬂuence a successful vaccination by
peptide- or lysate-pulsed DC: (1) Generation of DC; (2) Selection
of tumour-antigen pulsing of DC; (3) Transfection into DC; and
(4) Route of application of DC.
Generation of DC
Physiologically, human DC are mainly localised in tissue and repre-
sent only a small portion of less than 0.5% of peripheral blood
leukocytes. For therapeutical purposes large numbers of DC are
needed.
DC can either be generated from proliferating CD34
+ bone
marrow precursor cells (Caux et al, 1996) – which differentiate
under a variety of different cytokines including SCF, Flt3, GM–
CSF, TGF-b and TNF-a – or from non-proliferating peripheral
CD14
+ cells (monocytes) (Sallusto and Lanzavecchia, 1994). Usually,
CD34
+ precursors mobilised by G-CSF are isolated by leukapheresis
to obtain high numbers of peripheral cells for therapeutical
purposes. These cells seem to be more efﬁcient in the activation of
tumour-speciﬁc CTLs than CD14
+ derived DC (Mortarini et al,
1997). CD34
+ cells expand 10–30-fold. Yields of 5610
6 cells per
leukapheresis are typically obtained. In contrast, monocytes are
abundantly present in peripheral blood and can be easily obtained
by peripheral blood drawings or leukapheresis. Protocols for the Received 15 May 2001; revised 15 March 2002; accepted 27 March 2002
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since 1994 (Romani et al, 1994; Sallusto and Lanzavecchia, 1994)
and have been used for both experimental and therapeutical
purposes. Here, leukocytes are prepared from peripheral blood using
Ficoll–Hypaque density centrifugation. Monocytes are isolated by
an adherence step and subsequently cultured in the presence of
GM–CSF, IL-4 and 10% FCS or alternatively – under serum free
conditions (Jonuleit et al, 1997; Thurner et al, 1999b) – with 1%
autologous plasma for 7 days (Figure 1). After 1 week the yield of
DC generated varies from about 25 to 50% of the starting popula-
tion. Yields of 0.5–2.0610
6 cells per 10 ml blood are typically
obtained. Adherent cells show cytoplasmic processes typical for
DC. After co-culturing with immunologic effector cells DC form
typical cluster.
DC display several antigens on their cell surface, all of which are
characteristic, but not speciﬁc. The most typical markers at present
are HLA-class-I-, -class-II-molecules and co-stimulatory markers
(CD80, CD86). Immature DC – obtained after 7 days of culture
with GM–CSF and IL-4 – can be grown to mature DC by co-
culturing with TNF-a, IL-6, IL-1b, and PGE2 or, alternatively, with
a so-called monocyte conditioned medium (MCM) for another 3
days (maturation phase) (Thurner et al, 1999b). In contrast to
immature DC, mature DC are much more potent in inducing
TH1 and CTL responses in vitro and are resistant to immunosup-
pressive effects of tumour-derived IL-10 (Steinbrink et al, 1999).
Therefore, mature DC have been used in recent vaccination proto-
cols (Thurner et al, 1999a). Table 2 shows major phenotypical and
functional differences between immature and mature DC.
Selection of tumour-antigen pulsing of DC
Small antigenic peptides (consisting of 8–10 amino acids) are
loaded directly from outside the cell on HLA-class-I-molecules,
whereas tumour-lysates – as a protein or oligopeptide (410
amino-acids) – are internalised by endocytosis into the antigen
presenting cell, processed and then presented with the HLA class-
II-molecule. Cross-presentation of tumour-lysate is possible, i.e.
the presentation of proteins or oligopeptides with HLA class-I-
molecules (Bennett et al, 1997). This implies that pulsing with
tumour-lysate or oligopeptides is also able to activate CD8
+ T-cells
immediately by the HLA-class-I-pathway and not only CD4
+ T-
cells by the ‘conventional’ HLA-class-II-pathway. CD40/CD40L
signalling via DC/CD4
+ T-cell-interaction is able to pre-activate
DC temporarily. Subsequently these CD4
+ T-cell-pre-activated
DC can generate cytotoxic responses in CD8
+ T cells (Bennett et
al, 1998).
The selection of the peptide used for vaccination, is inﬂuenced
by several factors: type of tumour, HLA class-I or -II of the patient,
successful induction of CTL-response in vitro or in vivo, etc. Today,
more than 50 melanoma-associated epitopes are known, which can
be recognised by T cells. These epitopes are presented via different
HLA class-I- and HLA class-II-molecules (e.g. HLA A1, HLA A2,
HLA DR4, ...). An optimal selection of these epitopes allows the
treatment of almost 100% of patients with peptide-pulsed DC
for the case of malignant melanoma.
Vaccination of tumour–patients with a single peptide can result
in peptide-speciﬁc cytotoxicity. In these cases tumour escape
mechanisms may be a problem, for example by the loss of
tumour-associated epitopes or of essential antigen presenting mole-
cules. This problem can be circumvented by the usage of polyvalent
vaccines in a single patient, i.e. the application of tumour lysates or
Table 1 Various clinical trials with tumour antigen pulsed DC
Tumour Pat. Antigen DC Delivery
Speciﬁc T cell
induction
Clinical
response Ref
Prostate carcinoma 39 LLHETDSAV Immature Intravenous yes yes (7/39) (Murphy et al, 1996)
Prostate carcinoma 21 Xenoantigen
(mouse PAP)
Immature Intravenous, intradermal, intralymphatic yes yes (6/21) (Fong et al, 2001)
B-cell lymphoma 4 Autologous
tumour
Immature Intravenous, id-protein pulsed DC,
KLH, SAF-1
yes yes (4/4) (Hsu et al, 1996)
B-cell lymphoma 35 Autologous
tumour
Immature Intravenous, id-protein pulsed DC,
KLH, SAF-1
yes yes (24/33) (Timmermann et al, 2002)
Melanoma EADPTGHSY Immature Intradermal, intravenous yes no (3/3) (Hu et al, 1996)
Melanoma 4 Autologous lysate Immature Intranodal, lysate pulsed DC,
KLH, FCS
? yes (2/4) (Nestle et al, 1998)
Melanoma 12 MLLAVLYCL
AAGIGILTV
KTWGQYWQV
EADPTGHSY
EVDPIGHLY
Immature Intranodal, peptide pulsed DC,
KLH, FCS
? yes (3/12) (Nestle et al, 1998)
Melanoma 12 EVDPIGHLY Mature Subcutaneous, intradermal, intravenous,
peptide pulsed DC
yes yes (6/12) (Thurner et al, 1999a)
Medullary thyroid carcinoma 7 CEA, calcitonin Mature Subcutaneous yes yes (1/7) (Schott et al, 2001)
Pediatric solid tumours 15 Autologous lysate Immature Intradermal yes yes (6/15) (Geiger et al, 2001)
Injection into
lymph  node
Coincubation of DC
and tumorantigens
Tumor-
peptides
Tumor-
lysate
Excision of
tumour
Blood (monocytes,
stem cells) Cytokines
(GM-CSF+IL-4)
In vitro generation
of DC (7 days)
Maturation of DC (3 days)
(GM–CSF, IL-4, IL-1b,
IL-6, TNF-a PGE2)
Figure 1 Schematic diagram of dendritic cell generation.
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observed in a subgroup of a trial conducted by Nestle et al
(1998). Patients treated with tumour–lysate showed highest
response rates (50%, two out of four) compared to patients treated
with peptides alone (25%, three out of 12) (Table 1).
Tumour-associated peptides do bind with a deﬁned afﬁnity both
to the HLA molecules (i.e. HLA class-I and HLA class-II) and the
TCR. Whether this peptide is useful for therapeutical purposes or
not mainly depends on the degree of its afﬁnity. Low afﬁnity to
the HLA molecules is synonymous with low potency in CTL induc-
tion, whereas high afﬁnity means high potency in CTL induction
(Sette et al, 1994). Therefore, vaccination was performed with a
so-called heteroclitic peptide. Original melanoma-associated
peptides show a substitution of one amino acid with another at
the same position. Heteroclitic peptides, that are changed at the
HLA-binding motif to achieve a higher afﬁnity between the HLA
and the peptide, are potent immunogens. They are able to elicit
cross-reactivity with the original peptide, because the TCR-binding
motif remains unchanged. As a consequence a tumour-protective
immune response against the original peptide can occur after vacci-
nation with the heteroclitic peptide (Rosenberg et al, 1998).
Transfection into dendritic cells
Enhancing the immunogenicity of tumour cells is an interesting
approach to cancer gene therapy (Schmidt-Wolf et al, 1994). Cyto-
kine genes have been used in most instances to enhance tumour
immunogenicity (Schmidt-Wolf and Schmidt-Wolf, 1996). DC
are attractive targets of gene transfer since DC are easily accessable
and since these cells seem to be sensitive to immunologic strategies.
For further enhancement of the antigeneic presentation by DC
various genes like the genes for interleukin-7 (Westermann et al,
1998), GM–CSF, interleukin-12, interferon-gamma and interfer-
on-alpha (Tu ¨ting et al, 1998) have been transfected into DC. Up
to 10% transfection efﬁciencies using electroporation for gene
transfer into CD83
+ mononuclear cell derived DC were reported.
Other non-viral techniques produce robust DC transfection with
17% of monocyte-derived DC using cationic peptide or report
the ability of using lipofection in principle.
Higher efﬁciencies can be achieved using viral vectors. Adenoviral
vectors seem to be the most efﬁcient transfection method (Mulders
et al, 1998). Fifty to 85% transfected CD83
+ DC generated from
PBMC were reported. Thirty to 40% of precursor DC derived from
human umbilical cord blood can be transduced using adenoviral
vectors without cytopathic effect. With the aid of liposome-
mediated infection, gene transfer into CD83
+ DC resulted in more
than 90% of the cells transduced. Using a protocol with UV-irra-
diated adenoviruses similar results can be obtained without
addition of liposomes (Mulders et al, 1998; Ma ¨rten et al, 2001).
Adenoviral vectors can also be used for transduction of CD34
+ cell
derived DC (Bregni et al, 1998). For retroviral vectors a transduction
efﬁciency of 10–30% has been reported; other groups described a
resistance of DC to transduction by retroviral vectors. Recently,
there were reports of using other viral vectors like fowlpox virus,
lentivirus, avipoxvirus or vaccinia virus (Di Nicola et al, 1998).
Route of application of DC
Cell-based immunotherapy strategies using peptide- or lysate-
pulsed DC require interaction between DC and T cells. Physiologi-
cally, bone marrow-derived DC or their progenitors migrate to
tissues of inﬂammation, internalise antigens and subsequently
reach the paracortex of the lymph nodes (Steinman, 1991) and
the periarteriolar lymphoid sheath of the spleen (PALS). Here,
DC prime naive T cells. The optimal route of administration of
in vitro-cultured DC for migration to T-cell-rich sites is unknown,
particularly since migratory capacity of cultured tumour-antigen-
pulsed DC may be altered. Possible routes of administration are
intradermal, subcutaneous, intranodal, intravenous and intraperito-
neal injection of DC. Except intraperitoneal injection, which was
performed in animal studies only, all of these applications have
been employed in human cell-based vaccination protocols (Table
1). To examine migration patterns of DC, they were radioactively
labelled with indium-111. Subsequently, tumour antigen-pulsed
DC were administered by an intravenous, subcutaneous, or intra-
dermal injection in patients with metastatic malignancies (Morse
et al, 1999): Three patients received intravenous injection, four
patients received intradermal or subcutaneous injections simulta-
neously on both sides of their body. Intravenous injection
revealed highest activity in the lungs after 1 min, which decreased
continuously and redistributed after 24 h to highest spleen and
liver activities. No activity was found in lymph nodes and tumour.
Subcutaneous injection showed no activity in the lymph nodes. It
could not be detected where the injected DC remained. Intradermal
injection revealed highest activity in the draining lymph nodes after
24 h. Only 0.1–0.4% of relative activity was found here, i.e. only
4000 of 10
6 injected cells reached the lymph node in contrast to
10
6 of 10
6 cells after successful intranodal injection. In conclusion,
greatest activity in lymph nodes was only found after intradermal
injection. Subcutaneous injection seemed to be ineffective and
intravenous injection showed accumulation in the spleen as a T-
cell-rich area. Technetium-labelled immature monocyte-derived
DC have also been shown to migrate rapidly to the draining lymph
nodes after intradermal injection (Thomas et al, 1999). Nonethe-
less, injecting DC directly into the lymph node seemed to deliver
highest numbers of DC in T-cell-rich area, although this mode
of application may destroy the normal architecture of the lymph
node.
Studies where antigens were continuously injected into a lymph
node, for example by a pump, have yet to be performed in
humans. It has been shown that route and kinetic of peptide
administration determine its immunogenicity. This may also be
the case for DC administration.
Adverse effects
Peptide- or tumour-lysate pulsed DC are able to induce CTL-
response in patients with malignant melanoma. Peptide or
tumour-lysate antigens, used for DC vaccination, are normally
not restricted to tumour tissue, but can be found at least partially
on healthy tissue. Therefore a risk for the development of autoim-
mune diseases exists, that has been shown in animal models
(Ludewig et al, 2000). Pilot clinical studies in humans could not
ﬁnd clinical signs of auto-immunity except vitiligo and the occur-
rence of auto-antibodies (anti-TSH-receptor-Ab, ANA).
Unexpectedly, vaccination with tumour-lysate pulsed DC did not
show a higher incidence of auto-immunity than vaccination with
peptide-pulsed DC. The occurrence of IgG, IgM and IgE antibodies
to bovine serum albumin (BSA) causing anaphylaxis after vaccina-
tion with human peptide-pulsed DC was reported (Mackensen et
al, 2000). Therefore, for therapeutical ex vivo applications the use
of serum-free generated DC was recommended.
More frequently systemic ﬂu-like symptoms occurred: fever or
painful swelling of the injected lymph node (after intranodal injec-
Table 2 Phenotypical and functional differences between immature and
mature DC
Immature DC Mature DC
CD83 7 ++
CD80 (B7.1), CD86 (B7.2) + +++
HLA-class I/HLA-class II + +++
CD11a, CD11b, CD11c + +++
Motility + ++
Endocytosis ++ +/7
T-cell stimulation + +++
Dendritic cells for cancer therapy
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and erythema at the injection site could be detect. These reactions
regressed within 48–72 h.
Induction of tolerance against tumour cells may be a problem,
although recent studies pointed out the possible therapeutical value
of DC vaccination.
Future developments
In conclusion, DC are able to increase the tumouricidal activity of
immunologic effector T cells against tumour cells. This ability
depends on several factors as has been discussed. Nonetheless,
factors that inﬂuence effectively DC-activation of T cells against
tumour cells have to be optimised. The generation of DC-subtypes
that are more effective than those known today seems to be promis-
ing in inducing tumouricidal, speciﬁc immune responses not only
in patients with malignant melanoma, but other malignant diseases.
DC-based cell therapy will not only be conducted in patients with
distant metastases, but also in patients with minimal residual disease
or in adjuvant settings for high risk situations, where tumour-load
is low and therefore tumours can be recognised speciﬁcally and
eliminated effectively by DC-activated immunologic effector cells.
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